Types of Wearables Used in Modern Clinical Trials

Published on 21/12/2025

Wearable Devices Transforming Modern Clinical Trials

Table of Contents

Introduction: A Paradigm Shift in Clinical Trial Data Collection

Wearable technology is no longer a futuristic concept—it’s a present-day enabler of transformation in clinical trials. The convergence of biosensors, artificial intelligence, and miniaturized electronics has led to an explosion of wearable devices that are now central to decentralized clinical trials (DCTs). These devices are enabling real-time, patient-generated data collection in naturalistic settings, offering a richer understanding of patient health outside traditional clinical sites.

The use of wearable devices—ranging from smartwatches and ECG monitors to glucose sensors and smart patches—improves trial outcomes by reducing protocol deviations, increasing adherence, and minimizing patient burden. They also support GxP-compliant data strategies when properly validated, and align with the growing trend toward patient-centric research.

1. Smartwatches and Fitness Trackers

Smartwatches, including FDA-cleared models like the Apple Watch Series 4 and Fitbit Sense, are among the most popular wearables in clinical trials. These devices are capable of continuously collecting physiological metrics such as:

✅ Heart rate and variability (HRV)
✅ Step count and movement patterns
✅ Energy expenditure
✅ Sleep duration and quality
✅ Blood oxygen saturation (SpO₂)

Smartwatches are widely used in studies related to cardiovascular health,

insomnia, anxiety, and metabolic disorders. Sponsors typically integrate smartwatch data with Electronic Data Capture (EDC) systems via secure Bluetooth and cloud APIs. Real-world example: A global obesity trial conducted in five countries used Apple Watch-linked apps to track daily caloric expenditure and correlate it with treatment outcomes.

2. Continuous Glucose Monitoring (CGM) Devices

CGM systems like Abbott’s FreeStyle Libre and Dexcom G7 are transforming diabetes and metabolic disorder trials. These devices offer interstitial glucose measurements at frequent intervals (every 1–5 minutes), enabling dynamic glucose profiling. Their utility includes:

✅ Eliminating the need for finger-prick tests
✅ Detecting nocturnal hypoglycemia
✅ Real-time alerts and trend visualization

Because CGMs operate passively, they encourage better adherence and reduce missing data. Data from CGMs is increasingly being used to establish digital biomarkers for primary and secondary endpoints. In one notable crossover trial, CGM metrics were used alongside traditional HbA1c to support early regulatory submission for a new GLP-1 agonist.

3. Wearable ECG and Arrhythmia Monitors

Cardiac wearables such as the Zio Patch, BioBeat, and AliveCor’s KardiaMobile provide clinical-grade ECG monitoring for up to 14 days. These are commonly deployed in oncology, CNS, and cardiovascular drug trials where QT interval prolongation or arrhythmic events are a safety concern. Key features include:

✅ Multi-day single-lead ECG recording
✅ Remote arrhythmia detection and classification
✅ Data upload through patient mobile apps or secure hubs

These wearables reduce the need for Holter monitors and frequent clinic visits, streamlining data collection and improving patient experience.

4. Smart Patches and Biosensors

Single-use or reusable adhesive biosensors, such as VitalPatch and MC10 BioStamp, offer multiparameter monitoring capabilities. Common features include:

✅ Core and surface body temperature tracking
✅ Respiratory rate measurement
✅ Fall and activity detection
✅ Skin conductance and hydration levels

These are particularly valuable in studies involving oncology, geriatric, and neuromuscular disorders where traditional monitoring may be cumbersome. Biosensors have been validated under ISO 10993 for skin safety and are often incorporated into adaptive protocol designs to capture real-time deterioration events.

5. Pulmonary and Respiratory Monitoring Wearables

Wearable spirometry tools such as NuvoAir and Propeller Health help measure FEV1, FVC, and PEF parameters in patients with asthma, COPD, or interstitial lung diseases. These devices are often paired with inhaler sensors to assess compliance. Key trial applications include:

✅ Early detection of exacerbations
✅ Treatment response modeling
✅ Dose titration studies in pulmonary trials

Example: In a Phase II COVID-19 antiviral trial, wearable pulse oximeters and spirometers were used to monitor lung function remotely. Data collected helped identify candidates for hospitalization ahead of clinical symptom progression.

6. Wearables for Sleep and Circadian Rhythm Monitoring

Devices like the Oura Ring, Dreem headband, and Fitbit Sense use motion sensors and heart rate variability to assess sleep architecture. These are especially relevant in CNS studies involving insomnia, depression, or PTSD. Sleep-related endpoints captured by wearables include:

✅ Sleep latency and efficiency
✅ REM/NREM cycle detection
✅ Wake after sleep onset (WASO)

Wearables allow sponsors to collect sleep data over extended periods without sleep labs, thus improving external validity and reducing costs. A pivotal insomnia trial utilized wearable sleep bands and correlated wearable data with ePRO assessments and actigraphy.

7. Smart Clothing and Embedded Sensor Garments

Smart textiles, including shirts, leggings, and socks embedded with sensors, are emerging tools in the musculoskeletal and metabolic disease space. These can measure:

✅ Gait analysis and fall risk assessment
✅ Muscle fatigue and EMG signals
✅ Postural changes and joint motion

For example, a wearable sock embedded with pressure sensors was used in a diabetic foot ulcer prevention study, where pressure redistribution guided intervention. These garments are still under evaluation for full GxP validation, but their potential is vast in pediatric and rehabilitation studies.

8. Challenges and Considerations in Regulatory Validation

While wearable adoption is growing, regulators like the FDA and EMA emphasize the importance of validation and data traceability. Considerations include:

✅ Clinical validation of sensors under 21 CFR Part 11 and Annex 11
✅ Data accuracy, sampling frequency, and latency
✅ Secure data transmission and endpoint calculation transparency

Regulatory guidance on digital health technologies, such as FDA’s Digital Health Center of Excellence, offers a blueprint for sponsors. For detailed references, visit FDA’s Digital Health Guidelines.

9. Integration with Clinical Trial Platforms

Wearable data must be securely integrated with clinical systems such as CTMS, EDC, and ePRO platforms. API-driven architectures allow for real-time synchronization. Middleware platforms like Medidata Sensor Cloud and Validic have emerged to help translate raw data into protocol-relevant variables.

When integrating wearables into trials, sponsors should consider:

✅ End-to-end data provenance mapping
✅ Audit trails and version control for firmware updates
✅ SOPs covering device use, maintenance, and data handling

Refer to PharmaSOP: Blockchain SOPs for Pharma for templates and compliance tools tailored for wearables in regulated trials.

10. Future Trends and Use Cases

As technology evolves, wearables are expected to offer more advanced features like multi-analyte sensing, AI-driven health forecasting, and autonomous data verification. Emerging trial use cases include:

✅ Virtual site visits using wearable-enabled telemedicine
✅ Digital twins in trial simulation
✅ Passive assessment of neurocognitive decline

One ongoing Alzheimer’s study uses motion and vocal pattern sensors to predict mild cognitive impairment, integrating data into predictive models. As the ecosystem matures, wearable data will move from supportive to primary endpoints in many indications.

Conclusion

Wearables are redefining the landscape of clinical trials by enabling decentralized, continuous, and patient-centric data collection. With proper validation, regulatory alignment, and secure integration, these technologies can reduce site burden, lower costs, and enhance the richness of clinical evidence. The future of clinical research is not just digital—it’s wearable.